Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

WHO approves world's first malaria vaccine
Malaria is a leading cause of childhood illness and death in sub-Saharan Africa.
Pilot study led to a 30 per cent reduction in severe malaria in parts of Africa.

The World Health Organization (WHO) has recommended the use of a malaria vaccine among children in countries with moderate to high transmission of the disease.

The recommendation of the RTS, S malaria vaccine is the result of an ongoing pilot study taking place in Ghana, Kenya and Malawi, which has reached more than 800,000 children since 2019.

WHO director-general Dr Tedros Adhanom Ghebreyesus dubbed the long-awaited vaccine as a “historic moment” and that it “could save thousands of young lives each year”.

Spread by the P.falciparum parasite, malaria is a leading cause of childhood illness and death in sub-Saharan Africa; every year the disease kills more than 260,000 children in the region aged under five. 

In recent years, however, the WHO and partners have been reporting a stagnation in progress against the disease.

Dr Matshidiso Moeti, WHO regional director for Africa, commented: "For centuries, malaria has stalked sub-Saharan Africa, causing immense personal suffering. We have long hoped for an effective malaria vaccine, and now for the first time ever, we have such a vaccine recommended for widespread use.”

To date, more than 2.3 million doses of the RTS, S vaccine, developed by GSK, have already been administered as part of the pilot study. Key findings show that the vaccine is feasible to deliver, safe and cost-effective, even in areas with high malaria transmission. 

In the countries where the vaccine was administered, there was a 30 per cent fall in deadly severe malaria, even where malaria nets are used and there is good access to diagnosis and treatment. 

Dr Tedros said: “This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control. Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.” 

Later this year, Gavi, the Vaccine Alliance is expected to consider financing a broader vaccine rollout across Africa. The WHO will also work with regional health organisations about whether to adopt the vaccine as part of national malaria control strategies.

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.